Reversal of Collapsing Glomerulopathy in Mice with the Cyclin-Dependent Kinase Inhibitor CYC202

Journal of the American Society of Nephrology

Volumn 15, Issue 5, 2004, Pages 1212-1222

  Gherardi, Dana ^a   D'Agati, Vivette ^b   Chu, Te Hua Tearina ^c   Barnett, Anna ^e   Gianella Borradori, Athos ^e   Gelman, Irwin H ^d   Nelson, Peter J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia Univ Coll of Phys/Surgs ^*  (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e CYCLACEL LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; ROSCOVITINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; GLOMERULOPATHY; HUMAN IMMUNODEFICIENCY VIRUS 1; KIDNEY EPITHELIUM; MOUSE; NEPHRON; NEPHROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEROLOGY; TRANSGENE; URINALYSIS;

EID: 1942506665     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000124672.41036.F4     Document Type: Article

References (41)

1. Laurinavicius A, Rennke HG: Collapsing glomerulopathy - A new pattern of renal injury. Semin Diagn Pathol 19: 106-115, 2002
2. Schwimmer JA, Markowitz GS, Valeri A, Appel GB: Collapsing glomerulopathy. Semin Nephrol 23: 209-218, 2003
3. Detwiler RK, Falk RJ, Hogan SL, Jennette JC: Collapsing glomerulopathy: A clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int 45: 1416-24, 1994
4. Valeri A, Barisoni L, Appel GB, Seigle R, D'Agati V: Idiopathic collapsing focal segmental glomerulosclerosis: A clinicopathologic study. Kidney Int 50: 1734-1746, 1996
5. Laurinavicius A, Hurwitz S, Rennke HG: Collapsing glomerulopathy in HIV and non-HIV patients: A clinicopathological and follow-up study. Kidney Int 56: 2203-2213, 1999
6. Schwartz MM, Evans J, Bain R, Korbet SM: Focal segmental glomerulosclerosis: Prognostic implications of the cellular lesion. J Am Soc Nephrol 10: 1900-1907, 1999
7. Barisoni L, Mokrzycki M, Sablay L, Nagata M, Yamase H, Mundel P: Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 58: 137-143, 2000
8. Nagata M, Horita S, Shu Y, Shibata S, Hattori M, Ito K, Watanabe T: Phenotypic characteristics and cyclin-dependent kinase inhibitors repression in hyperplastic epithelial pathology in idiopathic focal segmental glomerulosclerosis. Lab Invest 80: 869-880, 2000
9. Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, D'Agati V, Alpers CE: Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: Role in podocyte proliferation and maturation. Kidney Int 58: 674-683, 2000
10. Yang Y, Gubler MC, Beaufils H: Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HIV-associated nephropathy. Nephron 91: 416-23, 2002
11. Ross MJ, Bruggeman L, Wilson PD, Klotman PE: Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J Am Soc Nephrol 12: 2645-2651, 2001
12. Pabst R, Sterzel RB: Cell renewal of glomerular cell types in normal rats. an autoradiographic analysis. Kidney Int 24: 626-631, 1983
13. Nadasdy T, Laszik Z, Blick KE, Johnson LD, Silva FG: Proliferative activity of intrinsic cell populations in the normal human kidney. J Am Soc Nephrol 4: 2032-2039, 1994
14. Knockaert M, Greengard P, Meijer L: Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 23: 417-425, 2002
15. Senderowicz AM, Sausville EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 92: 376-387, 2000
16. Davies TG, Pratt DJ, Endicott JA, Johnson LN, Noble ME: Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol Ther 93: 125-133, 2002
17. Fuente C, Maddukuri A, Kehn K, Baylor SY, Deng L, Pumfery A, Kashanchi F: Pharmacologic cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics. Curr HIV Res 1: 132-152, 2003
18. Nelson PJ, Gelman IH, Klotman PE: Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. J Am Soc Nephrol 12: 2827-2831, 2001
19. Schang LM, Bantly A, Knockaert M, Shaheen F, Meijer L, Malim MH, Gray NS, Schaffer PA: Pharmacologic cyclin-dependent kinase inhibitors inhibit replication of wild type and drug-resistant strains of HSV and HIV-1 by targeting cellular, not viral proteins. J Virol 76: 7874-7882, 2002
20. Wang D, Fuente C, Deng L, Wang L, Ziberman I, Eadie C, Healey M, Stein D, Denny T, Harrison LE, Meijer L, Kashanchi F: Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol 75: 7266-7279, 2001
21. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH: Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 275: 28345-8, 2000
22. Nelson PJ, Sunamoto M, Husain M, Gelman IH: HIV-1 expression induces cyclin D1 expression and pRb phosphorylation in infected podocytes: Cell-cycle mechanisms contributing to the proliferative phenotype in HIV-associated nephropathy. BMC Microbiol 2: 26, 2002
23. Dickie P, Felser J, Eckhaus M, Bryant J, Silver J, Marinos N, Notkins AL: HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 185: 109-119, 1991
24. Kopp JB, Klotman ME, Adler SH, Bruggeman LA, Dickie P, Marinos NJ, Eckhaus M, Bryant JL, Notkins AL, Klotman PE: Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci U S A 89: 1577-1581, 1992
25. Barisoni L, Bruggeman LA, Mundel P, D'Agati VD, Klotman PE: HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. Kidney Int 58: 173-181, 2000
26. Nelson PJ, D'Agati VD, Gries JM, Suarez JR, Gelman IH: Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol. J Antimicrob Chemother 51: 921-929, 2003
27. Pippin JW, Qu Q, Meijer L, Shankland SJ: Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 100: 2512-2520, 1997
28. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP: In vitro and in vivo antitumor properties of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102: 463-468, 2002
29. Bruggeman LA, Dikman S, Meng C, Quaggin SE, Coffman TM, Klotman PE: Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 100: 84-92, 1997
30. Pelech S, Zhang H: Plasticity of the kinomes in monkey and rat tissues. Sci STKE 2002: PE50, 2002
31. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science 298: 1912-1934, 2002
32. Dancey J, Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2: 296-313, 2003
33. Bruggeman LA, Ross MD, Tanji N, Cara A, Dikman S, Gordon RE, Burns GC, D'Agati VD, Winston JA, Klotman ME, Klotman PE: Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 11: 2079-2087, 2000
34. Hiromura K, Petermann AT, Blonski MJ, Krofft RD, Mundel P, Shankland SJ: Cyclin-dependent kinase 5 is required for podocyte differentiation and shape [Abstract]. J Am Soc Nephrol 13[Suppl]: 32A, 2002
35. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM: Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2: 41.1-41.11, 2001
36. Chao SH, Price DH: Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276: 31793-31799, 2001
37. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar Y: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci U S A 99: 8301-8305, 2002
38. Weiner NJ, Goodman JW, Kimmel PL: The HIV-associated renal diseases: Current insight into pathogenesis and treatment. Kidney Int 63: 1618-1631, 2003
39. Monini P, Sgadari C, Barillari G, Ensoli B: HIV protease inhibitors: Antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity. J Antimicrob Chemother 51: 207-211, 2003
40. Goldberg AL, Rock K: Not just research tools-Proteasome inhibitors offer therapeutic promise. Nat Med 8: 338-340, 2002
41. Abbate M, Remuzzi G: Can we really lessen kidney damage to the point that the loss of renal function of progressive nephropathy may revert? J Am Soc Nephrol 14: 1411-1414, 2003